Dopamine and Androgen Receptor Signaling: Novel Insights in Cancer Biology
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 31
Special Issue Editor
Interests: receptor pharmacology; cancer genomics; biomarker discovery; DNA-RNA biology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue aims to explore the intricate interplay between dopamine and androgen receptor (AR) signaling pathways and their emerging roles in cancer biology. Recent studies have highlighted the significance of neurotransmitter and hormone receptor crosstalk in modulating tumor progression, metastasis, and therapeutic resistance, particularly in hormone-sensitive cancers such as prostate and breast cancer. By bringing together cutting-edge research, this Special Issue seeks to uncover novel molecular mechanisms, identify potential biomarkers, and evaluate therapeutic strategies targeting these signaling axes. A key focus will also be on the screening of new chemical libraries to identify compounds that modulate dopamine and AR signaling, offering promising avenues for drug discovery and development. Contributions that investigate the translational potential of targeting these pathways in cancer treatment are especially encouraged.
Dr. Srijan Acharya
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- dopamine signaling
- androgen receptor
- cancer biology
- hormone-sensitive tumors
- signal transduction
- tumor microenvironment
- neurotransmitters in cancer
- prostate cancer
- breast cancer
- targeted therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
